....because there will be enough goods news from ACT over the next of months to drive the share price above $5 per share, even with their 3B+ shares outstanding, then they can uplist to Nasdaq, which will drive the share price even higher. Then when EMA allows them to commercialize their cures, they can start buying back shares from their huge profits, thus ending this nonsense, once and for all, about doing a RS.
Actually, I'm in the no R/S camp, too. Think SIRI ... they had over 2B shares, I think, when they were about .10, too. Everybody kept screaming that they could NEVER get above $1. It's not unheard of with this share structure to make your way out of the weeks. PIR was about .38 cents and now sells for over $20, selling #$%$ from China. Anybody who thinks getting uplisted will stop the nonsense and this will trade rationally, hasn't owned many start up biotechs. As for institutional investors? Build it and they will come!!
Other than keepees normal nonsense (and he's still in semi pump mode) the bashers have laid off this stock the last day or two...
Correction: keepee is now in full pump mode, watch for his "switch".
Come on now, keep.
There is NOTHING that we currently know about that would jump the PPS by a factor of 70 or more.
Over the course of 2-3 years, maybe. Next couple of months? Not a snowball's chance!!!
Of course, IMO.
The Top Line Data peer review when released to the public, and the move to Ph 2, along with the EMA soon after allowing orphan drug status AMD & SMD, will do the trick. Then there's the good old IRRATIONAL EXUBERANCE kick in, where everyone madly jumps in driving the share price far higher than it should be.
you are the idiot Matt Vincent just went public in vivo magazine that MORE Than 1/2 the patients reversed their blindness, um er uh, and some spectacular, we all know about the cowboy from 400/20 to 40/20. That is like introducing penicillin to the public for the first time, you fool. a 55 billion dollar market and it only costs ACTC $ 100.00 dollars to make a single injection. You are dead wrong even with a 3 billion float $ 3.00 is in the bag and the poster is probably right about the $ 5.00 dollars a share as soon as the peer reviewed article is released, couple that with the partnership, and the institutional financing. The partnership alone will bump to $ 2.00 dollars, go ahead and sell idiot I am buying all I can